secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2021-11-23T23:59:59+00:00
Accession:  0001485003-21-000226
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sesen Bio director Jane Pritchett Henderson resigns from Board, becomes CEO Advisor
--------------------------------------------------------------------------------

- Jane Pritchett Henderson resigned from Sesen Bio's Board effective Nov. 22, 2021, to focus on other roles including CFO at Adagio Therapeutics.
- She transitions to CEO Advisor role; no disagreement with company policies or operations.
- Jason Keyes named Chair of Audit Committee; Board Chair Jay Duker assumes Chair of Compensation Committee.
- Board now has six directors, all independent except CEO Thomas Cannell.
- Henderson joins five other executives already serving as CEO Advisors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000148500321000226/0001485003-21-000226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000148500321000226/sesn-20211122.htm
  HTML page:      https://secwatch.observer/filing/0001485003-21-000226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer